Single agent bortezomib results in response rates of 51% in patients with newly diagnosed multiple myeloma and is touted to be especially effective in high-risk disease. We are the first to prospectively explore single agent bortezomib as primary therapy (induction, maintenance and re-induction) without consolidative autologous stem cell transplant in a cohort selected to have high-risk multiple myeloma. Patients received eight cycles of induction, followed by maintenance bortezomib every other week, indefinitely. Patients relapsing on maintenance had the full induction schedule resumed. On an intention-to-treat basis, the response rate (Xpartial response) was 48%. Among seven patients who progressed on maintenance bortezomib and received re-induction, two responded to the treatment. With a median follow-up of 48.2 months, 1-and 2-year overall survival probabilities were 88% (95% confidence interval (CI) 79 -98%) and 76% (95% CI 60-86%), respectively. Median progression-free survival was 7.9 months (95% CI 5.8-12.0). Twenty-three and thirty-four patients had Xgrade 3 hematological and non-hematological toxicity, respectively, with treatment-emergent neuropathy in 7% with motor grade 1-2, 56% with sensory grade 1-2 and 2% with grade 3, and in 14% with neuropathic pain grade 1-2 and 2% with grade 3. In high-risk patients, upfront bortezomib results in response rates that are comparable to those reported for unselected cohorts, but single agent bortezomib is not sufficient as primary therapy.
Introduction
Multiple myeloma is a malignant plasma cell disorder that can result in highly disparate outcomes based on heterogeneous biology. 1 Over the past decade, the introduction of high-dose chemotherapy with peripheral blood stem cell transplant and novel agents such as thalidomide, bortezomib and lenalidomide has substantially impacted the natural history of the disease. 2, 3 However, it is well accepted that patients with high-risk disease with high beta-2 microglobulin levels, high proliferative rates and cytogenetic abnormalities of their plasma cells fare poorly with alkylator-based therapy, be it standard dose or dose intensive with hematopoietic stem cell support. 4 It is unclear whether the negative prognostic impact will be abrogated by the application of novel therapies. Preliminary data generated by post-hoc analyses would suggest that the negative impact of deletion 13 is abrogated by the proteasome inhibitor, bortezomib. 5, 6 With this in mind, we designed a trial to prospectively evaluate the effect of upfront bortezomib has on the response rate, 1-and 2-year progression-free survival (PFS) and overall survival (OS) among patients with high-risk multiple myeloma.
Materials and methods

Eligibility
Patients were eligible to enter into the study if they had an earlier untreated symptomatic multiple myeloma that was 'high-risk,' as defined by any of the following: beta-2 microglobulin level X5.5 mcg/ml; a bone marrow plasma cell labeling index of X1%; or deletion 13q by metaphase cytogenetics. Patients were required to have a measurable disease defined as serum monoclonal protein level 41.0 g per 100 ml and/or urine monoclonal protein level 4200 mg every 24 h. Patients also needed to have hemoglobin level 47 g per 100 ml, platelet count 450 000 cells per ml, absolute neutrophil count 41000 cells per mcl, creatinine level o3 mg per 100 ml, bilirubin level p1.5 mg per 100 ml, and alanine aminotransferase and aspartate aminotransferase levels p2.5 times the upper limit of normal. No earlier systemic therapy, with the exception of bisphosphonates, was permitted. In addition, patients with grade 2 or higher peripheral neuropathy (PN), active infection, current or previous deep vein thrombosis and having an Eastern Cooperative Oncology Group performance score of 3 or 4 were excluded. The study was approved by the National Institutes of Health Central Institutional Review Board, as well as by institutional review boards of the participating institutions.
The trial was started in January 2004 and forty-four patients enrolled from March 2004 to March 2005. The final analysis was performed on 2 July 2009. Accrual was scattered over 22 Eastern Cooperative Oncology Group institutions. One patient was ineligible because of missing baseline labs. One patient died before the treatment started. The analysis dataset includes forty-three patients for the toxicity evaluation and fortytwo eligible and treated patients for all other analyses. Two patients were unevaluable for response because of the following reasons: (1) participant 20001 was treated simultaneously with dexamethasone (protocol violation) and (2) the disease status of patient 20042 was assessable by urinary monoclonal protein level only, but urinary monoclonal protein level was not measured after baseline measurement. Although a third patient (participant 20035) died before the disease measurement could be done, he was included in the analysis dataset as his death could be related to treatment rather than to protocol violation.
Treatment schedule
The treatment schema is as shown in Figure 1 . Eligible patients were treated for 8 cycles of bortezomib 1.3 mg/m 2 on days 1, 4, 8 and 11 as induction every 21 days until toxicity or progression. Patients were required to receive a minimum of two cycles of bortezomib before removal from study for progressive disease. Patients had the option to collect stem cells after cycle 4. The number of cycles was to be reduced if the patient achieved complete response before cycle 6, that is, patients were to receive two cycles beyond complete response and then proceed to maintenance.
Maintenance therapy was for patients who completed induction without progression. The maintenance treatment schedule was 1.3 mg/m 2 on days 1 and 15 every 28 days until progression or excessive toxicity.
Response and toxicity criteria
The Blade response criteria 7 were used in addition to the very good partial response (PR) category, which included a X90% reduction of myeloma protein level from the serum and a urinary monoclonal spike of p100 mg/day. 8 To satisfy the primary end point of this study, a PR or better was required. All responses needed to be confirmed at least 6 weeks apart by two consecutive determinations. The National Cancer Institute Common Toxicity Criteria (version 2) were used to grade the adverse effects.
Laboratory correlates
The 24 patients who supplied research samples had fluorescence in situ hybridization performed to analyse the following baseline abnormalities: t(4;14)(p16.3;q32), t(14;16)(q32;q23) or deletion 17p13. The plasma cell labeling index and the fluorescence in situ hybridization studies were performed as earlier described.
9,10
Statistical design and analysis
The primary end point of this study was the induction response rate. A response rate to bortezomib of 50% was considered to be promising in this population. We assumed an ineligibility rate of about 10%, requiring 44 patients to be accrued to the trial in order to have 39 eligible patients. This design had 90% power to detect a response rate of 50% with a type I error rate of 9%, given a 30% response rate. Our hypothesis was that if we observed fewer than 16 responses among the 39 eligible patients, we would declare this treatment as ineffective. Secondary end points of this trial included evaluation of PFS, OS and response rates on maintenance as well as re-induction. Further, we set out to explore a possible differential outcome by defining risk characteristics. PFS and OS were estimated using the method of Kaplan and Meier.
For the PFS estimates, patients were counted as an event if they progressed or died without documented progression within 3 months of their last disease evaluation. Patients were censored at the date of their last disease evaluation if they were alive without progression. Patients were censored at the start of nonprotocol therapy if that occurred before disease progression or the last disease evaluation. Patients without disease assessments were censored at the time of registration. PFS was estimated from the date of registration and from the start of maintenance and re-induction. OS estimates did not censor for non-protocol therapy.
Results
Baseline characteristics
The baseline characteristics of the 42 eligible and treated patients are shown in Table 1 . Fifty percent of them were male Single-agent bortezomib induction in MM A Dispenzieri et al and the median age was 63 years (range 41-81). All patients had poor prognosis disease with at least one of the following negative factors: beta-2 microglobulin level X5.5 mg/ml, 76% (32/42); plasma cell labeling index X1%, 40% (17/42); and deletion 13q, 14% (6/42). Additional risk factors were examined in 24 patients: t(4:14) was present in 4 of them and deletion 17p in 2. None of the 24 patients tested harbored t(14;16). As not every patient had plasma cell labeling index and cytogenetics performed, these are likely underestimates.
Response
The overall induction response rate to single agent bortezomib in previously untreated high-risk myeloma patients was 48% PR or better ( Table 2 ). An additional 5% of patients achieved a minimal response. The median time to response was 1.3 months. If unevaluable patients are excluded (n ¼ 3), the respective induction response rates were 51 and 5%. For those who responded during induction, response rates were held during maintenance and there were no up-grades. The two patients who started maintenance in no response/stable disease experienced progression on maintenance therapy. Response rates did not differ with the various risk factors (data not shown).
Among the four patients recognized as having t(4;14), one was unevaluable, one experienced progressive disease (PD) and two responded (one with very good PR and one with PR). Among the seven patients who progressed on maintenance bortezomib and went on to re-induction, two responded. One patient experienced progression 6.6 months from their second confirmed PR date (time to response was 0.7 months after starting re-induction). The other patient is still on treatment with PR status held for 17.6 months (time to response was 3.4 months after starting re-induction). The distribution of risk factors among this group of seven patients was del 13q in one, high plasma cell labeling index in four and high beta-2 microglobulin level in three.
Survival/retention
With a median follow-up of 48.2 months, there have been 19 deaths (Figure 2) , including 1 possibly treatment-related death (heart block). The median OS was not reached. 1-and 2-year OS probabilities based on Kaplan-Meier estimates were 88% (95% confidence interval (CI) 79-98%) and 76% (95% CI 60-86%). Among the 42 eligible and treated patients, 28 (67%) had events. The median, 1-and 2-year PFS probabilities were 7.9 months (5.8-12.0 months), 36% (95% CI 29-59%) and 16% (5-33%), respectively (Figure 3a ). There were overlapping CIs for outcomes among the different risk factors.
The PFS for the 15 patients who were treated on maintenance therapy was estimated from the date of registration (Figure 3b ) and from start of maintenance (Figure 3c ). There was one patient who progressed before start of maintenance who was dropped from this analysis. Median PFS from the start of maintenance only was 7.8 months (95% CI 2.8-10.7 months). 1-and 2-year PFS probabilities were 25% (95% CI 9-67%) and 8.3% (95% CI 0.5-31%), respectively. Median PFS on re-induction only was 7.3 months (95% CI 4.1-36.9 months). 1-and 2-year PFS probabilities were the same: 22% (95% CI 1-62%).
Overall, the most common reason for patients to discontinue therapy was PD (n ¼ 18, 45%) followed by toxicity (n ¼ 7, 18%), Figure 1 . The median time from start to end of treatment was 4.2 months. The number of total treatment cycles ranged from 1 to 55. There are two patients who are still on treatment: cycle 45 data on maintenance (53 total cycles), and cycle 23 treatment data on re-induction (55 total cycles). Figure 1 shows the flow of patients and their reason for discontinuing therapy. Figure 2 Overall survival.
Single-agent bortezomib induction in MM A Dispenzieri et al
The median number of induction cycles administered was six, with 19 patients receiving all of the eight induction cycles. Fifteen patients continued into the maintenance phase of treatment, with the median number of maintenance cycles being 9 (range: 1-45 cycles). For the seven patients entering reinduction for progression while on maintenance, the median number of re-induction cycles was 3 (range 1-23).
Toxicity
All the 43 patients who received treatmentFincluding the one ineligible patientFwere included for the toxicity analysis. Only those adverse events adjudicated to be at least possibly related to treatment are reported. Table 3 summarizes adverse events reported by organ system and maximum grade. The maximum grade consolidates the reports of a given type of toxicity for a patient over time by taking the maximum across time (that is, a patient appears only once for a given type of toxicity). Twentythree patients had grade 3 hematological toxicity. Thirty-four patients (79%; 95% CI 64-90%) had grade 3 or higher nonhematological toxicity, including one patient with a lethal heart block. The most common non-hematological grade 1-4 and grade 3-4 toxicities included electrolyte disturbances, fatigue, neuropathy and gastrointestinal disturbances. Six patients (14%) had grade 4 non-hematological adverse events, predominantly electrolyte disturbances, but also one case each of sinus bradycardia and weight loss. Twenty-five patients developed treatment-emergent neuropathy. Considering all the 43 patients evaluable for toxicity, the breakdown of treatment-emergent neuropathy was as follows: motor grade 1-2 in 7%; sensory grade 1-2 in 56% and grade 3 in 2%; and neuropathic pain grade 1-2 in 14% and grade 3 in 2%.
Discussion
Although the current study is not the first report of the use of bortezomib as front-line therapy for symptomatic myeloma, it is unique. It is the only upfront bortezomib clinical trial that prospectively targeted high-risk patients, that tested maintenance bortezomib and that tested re-induction after relapse despite maintenance bortezomib. Unlike the four other publications describing the front-line use of single agent bortezomib, 11-14 our patients were not slated for a set number of cycles of therapy to be followed by high-dose chemotherapy with peripheral blood stem cell transplant. In fact, the most common reason for coming off active treatment was progression/relapse (45%), followed by death or adverse events (20%) and other complications of disease (7%). Only 10% of the patients withdrew for the specific reason of seeking alternative therapy.
We showed that among high-risk patients, single agent bortezomib induced OR rates of approximately 51%, which is comparable to those reported by others in a general myeloma 
Table 3
Number of patients with toxicity at least possibly related to treatment by system a (n ¼ 43) The maximum grade consolidates the reports of a given type of toxicity for a patient over time by taking the maximum across time (that is, a patient appears only once for a given type of toxicity). Organ systems were not included because only one patient with grade 1-2 toxicity was included in the auditory/ear, endocrine, renal/genitourinary and vascular analyses. b The breakdown of neuropathy is as follows: motor grade 1-2 in 3 patients; sensory grade 1-2 in 24 patients and grade 3 in 1 patient; and neuropathic pain grade 1-2 in 6 patients and grade 3 in 1 patient. c This includes 1 grade 5 cardiac death.
Single-agent bortezomib induction in MM A Dispenzieri et al population (Table 4) . [11] [12] [13] Moreover, the observed 2-year OS probability of 76% (95% CI 60-86%) was higher than expected for published rates for patients with international staging system 3 (58%) or high-risk cytogenetics (65%). 15, 16 In the present study, our 1-and 2-year PFS probabilities were 36% (95% CI 22-59%) and 16% (95% CI 5-33%), respectively. In comparison, Richardson et al.
14 reported on 64 patients treated with single agent bortezomib with an OR rate of 41% (complete response 3%, PR 38%). During their follow-up period of 29 months, 11 progressed and 32 underwent peripheral blood stem cell transplantation. Their 1-and 2-year PFS was 60 and 25%, respectively. Although Richardson et al. report that response rates did not differ based on the presence or absence of adverse cytogenetics, only deletion 13q by fluorescence in situ hybridization was evaluated.
Jagannath et al. 11 treated 32 newly diagnosed myeloma patients with bortezomib plus or minus dexamethasone. Twothirds of the patients received dexamethasone. The OR rate was 88%. As most patients underwent high-dose chemotherapy with peripheral blood stem cell transplantation, PFS is not cited. The 1-year OS was 87%. Harousseau et al.
12 treated 48 patients with first-line bortezomib and dexamethasone combination therapy, achieving an OR rate of 66%. All patients underwent high-dose peripheral blood stem cell transplantation, so no information was available regarding PFS or OS.
Finally, Rosinol et al. 13 treated 40 newly diagnosed symptomatic myeloma patients with six alternating cycles of bortezomib and dexamethasone. Sixty-five percent of the patients achieved a PR or better, challenging the notion that there is synergy with dexamethasone. Fluorescence in situ hybridization abnormalities did not have any impact on the response rate. As more than 90% of patients underwent planned autologous stem cell transplantation, the authors could offer no information about the durability of response or PFS.
Other more complex induction combinations have also been described, including bortezomib, doxorubicin, dexamethasone (PAD), pegylated doxorubicin/bortezomib, bortezomib, thalidomide, dexamethasone (VTD) and melphalan, prednisone, bortezomib (VMP). [17] [18] [19] [20] [21] These combinations have response rates approaching 90-100%, but are associated with more side effects, and their long-term effect on high-risk disease is not yet well understood. The VMP study offers some insight into bortezomib's performance among high-risk patients. These authors found that the 26 patients with high-risk cytogeneticsF including the t(4;14),t(14;16) translocations or deletion 17pFhad the same rate of complete response and, with a median follow-up of 16 months, similar times to progression and OS. 21 Extended use of bortezomib in the upfront setting has not been clarified based on the studies listed above with the possible exception of the Richardson et al.
14 study, in which half of their patients did not proceed immediately to hematopoietic stem cell transplantation. The estimated 30-month OS probability was 82% (95% CI 66-98%) for those patients who underwent hematopoietic stem cell transplantation and 78% (95% CI 63-92%) for those who did not undergo hematopoietic stem cell transplantation.
There are no prospective manuscripts on re-treatment with bortezomib in the upfront setting, but there are two retrospective reports. In the first report on those patients who had achieved a PR or better to their original bortezomib therapy, 31% (12 of 39) had a PR or better to re-treatment, which is similar to our rate of 29%. 22 In the second report, 63% of patients who had earlier responded to bortezomib responded to re-treatment with bortezomib (with concomitant dexamethasone in 2/3 of cases). 23 Finally, the preliminary results from the RETRIEVE study suggest that 40% response rates can be achieved in patients who are re-treated with bortezomib. 24 Finally, we offer further insight about the rates of bortezomib PN. A total of 58% developed grade 1-2 neuropathy and 16% developed painful PN. Grade 3 neuropathy was observed in 4% of patients. Richardson et al.
14 had similar findings: any sensory, painful, or motor PN in 64% (41/65), 13% (8/65), 11% (7/65), respectively, with a total of 5 patients (8%), with grade 3 PN. Rates of PN were comparable to those of the upfront study of Jagannath et al., 11 with grade 2-3 PN in 26% of participants. Rosinol et al. 13 found that only 22% of patients developed grade 1 PN and 2.5% of patients developed grade 2 PN. Harousseau et al. 12 also reported grade 2-3 peripheral neuropathy in 14% of cases.
This study is relevant because it provides important information about single agent bortezomib for patients with newly diagnosed high-risk myeloma. A limitation of this study is that patients with t(4:14) are under-represented partially because it Table 4 Bortezomib as induction for multiple myeloma Regimen Evaluable patients CR, % VGPR, % PR, % OR, % PFS OS was designed in 2002, a time before it was recognized that bortezomib may abrogate the risk of t (4;14) . Although 51% of patients achieved a response, the 1-and 2-year PFS rates were poor. It is worth knowing that even in high-risk patients, re-induction can be successful in 29% of patients failing maintenance. Although bortezomib appears to be equally efficacious in both high-risk and standard-risk patients, single agent bortezomib is not sufficient. Multidrug combinations are preferred in this high-risk population.
